Prognostic Value of XXXX PET/CT in Surgical @entity1149 : A Meta-Analysis.

@entity1 @entity419 @entity5 @entity1149 @entity204 @entity1349
BACKGROUND: The identification of surgical @entity1149 ( @entity1149 ) @entity1 with poor prognosis is a priority in clinical oncology because of their high 5-year mortality. This meta-analysis explored the prognostic value of maximal standardized uptake value (SUVmax), metabolic @entity5 volume (MTV) and total lesion glycolysis (TLG) on disease-free survival (DFS) and @entity1349 ( @entity1349 ) in surgical @entity1149 @entity1 . MATERIALS AND METHODS: MEDLINE, EMBASE and Cochrane Libraries were systematically searched until August 1, 2015. Prospective or retrospective studies that evaluated the prognostic roles of preoperative @entity419 PET/CT with complete DFS and @entity1349 data in surgical @entity1149 @entity1 were included. The impact of SUVmax, MTV or TLG on survival was measured using hazard ratios (HR). Sub-group analyses were performed based on disease stage, pathological classification, surgery only and cut-off values. RESULTS: Thirty-six studies comprised of 5807 @entity1 were included. The combined HRs for DFS were 2.74 (95%CI 2.33-3.24, unadjusted) and 2.43 (95%CI: 1.76-3.36, adjusted) for SUVmax, 2.27 (95%CI 1.77-2.90, unadjusted) and 2.49 (95%CI 1.23-5.04, adjusted) for MTV, and 2.46 (95%CI 1.91-3.17, unadjusted) and 2.97 (95%CI 1.68-5.28, adjusted) for TLG. The pooled HRs for @entity1349 were 2.54 (95%CI 1.86-3.49, unadjusted) and 1.52 (95%CI 1.16-2.00, adjusted) for SUVmax, 2.07 (95%CI 1.16-3.69, unadjusted) and 1.91 (95%CI 1.13-3.22, adjusted) for MTV, and 2.47 (95%CI 1.38-4.43, unadjusted) and 1.94 (95%CI 1.12-3.33, adjusted) for TLG. Begg's test detected publication bias, the trim and fill procedure was performed, and similar HRs were obtained. The prognostic role of SUVmax, MTV and TLG remained similar in the sub-group analyses. CONCLUSIONS: High values of SUVmax, MTV and TLG predicted a higher risk of recurrence or @entity204 in @entity1 with surgical @entity1149 . We suggest the use of FDG PET/CT to select @entity1 who are at high risk of disease recurrence or @entity204 and may benefit from aggressive treatments.
